Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03044132 · ClinicalTrials.gov registry record · NA
DermACELL AWM® in Chronic Wagner Grade 3/4 Diabetic Foot Ulcers
A NA study, sponsored by LifeNet Health.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT03044132: Completed NA study, sponsored by LifeNet Health.
NCT03044132 is a NA study that has completed, run by LifeNet Health. The registered enrollment target is 61 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03044132, a NA study, has completed, sponsored by LifeNet Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, clinical research trial evaluating the clinical outcomes of DermACELL AWM in dermal regeneration.
Primary Outcome
Days required for granular bed formation
Interventions
- OTHER DermACELL AWM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-01-15 |
| Est. Completion | 2018-12-31 |
| Phase | NA |
What the finished NCT03044132 record still lists
NCT03044132 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which DermACELL AWM is the first listed.
NCT03044132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03044132 about?
NCT03044132 is a clinical study titled "DermACELL AWM® in Chronic Wagner Grade 3/4 Diabetic Foot Ulcers". This is a prospective, multicenter, clinical research trial evaluating the clinical outcomes of DermACELL AWM in dermal regeneration.
What is the current status of trial NCT03044132?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2017-01-15. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT03044132?
The interventions under investigation include: DermACELL AWM (OTHER).
Who is sponsoring clinical trial NCT03044132?
This trial is sponsored by LifeNet Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03044132's enrollment target sits among peer trials
61 1164th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI